|Articles|May 1, 2007
eShowcase: CTSD Version 2.5
CTSD Version 2.5 provides improved data visualization and enhanced user interface
Advertisement
CTSD Version 2.5 provides improved data visualization and enhanced user interface
Phase Forward (Waltham, MA) has released Version 2.5 of its Clinical Trials Signal Detection (CTSD) system. CTSD detects, evaluates, and tracks potential safety signals, which allows biopharmaceutical companies to analyze and classify potential safety signals, develop a product safety profile, and make more informed decisions earlier in the drug development process.
CTSD 2.5 adds an enhanced user interface that features summary displays, data visualization tools, and access to trial data without programming. The user interface's interactive displays facilitate safety review workflow by including patient level drill downs, Lab Trend graphs, an Exposure Summary graph, and Kaplan-Meier plots. It also offers Hy's Law alerts and a full set of Standardized MedDRA Queries (SMQs).
The product is integrated with Phase Forward's Web Submission Data Manager (WebSDM) platform and offers CDISC support.
Phase Forward, (781) 890-7878, www.phaseforward.com
Articles in this issue
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025
- Vabysmo Shows Long-Term Efficacy and Safety in Wet AMD, PCV Patients
September 12th 2025
- Latest NIMBLE Study Results Highlight Progress in gMG Research
September 12th 2025
- ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug Trials
September 11th 2025
Advertisement
Advertisement